Table 1.
Features of the case reports included in the analysis.
| Author | Year | Country | Type | Number | Systemic disease | Eye involvement | Intervation |
|---|---|---|---|---|---|---|---|
| Philip B Meadow [8] | 2014 | America | Case report | 1 | RA | Keratitis | Tofacitinib |
| Stephanie Sarny [9] | 2018 | Austria | Case report | 1 | Psoriasis, MMP | Conjunctivitis | Baricitinib |
| Michael A. Paley [10] | 2019 | America | Case report | 2 | NA | Uveitis scleritis | Tofacitinib |
| P. Bauermann [11] | 2019 | Germany | Case report | 1 | JIA | Uveitis | Tofacitinib |
| Elisabetta Miserocchi [12] | 2020 | Italy | Case series | 4 | JIA | Uveitis | Baricitinib Tofacitinib |
| Richa Pyare [13] | 2020 | India | Case report | 1 | NA | Scleritis | Tofacitinib |
| Claudia Fabiani [14] | 2020 | Italy | Case report | 1 | RA | Scleritis | Tofacitinib |
JIA: juvenile idiopathic arthritis; RA: rheumatoid arthritis; MMP: mucous membrane pemphigoid; PsA: psoriatic arthritis; NA: not available.